Joseph Patti, PhD
President & CEO, Biota Pharmaceuticals
Joseph M. Patti, Ph.D. is currently the President and Chief Executive Officer and Board Member of Biota Pharmaceuticals, Inc., a publicly traded biopharmaceutical company focused on the development of novel drugs to treat life-threatening viral respiratory infections. Previously, Dr. Patti was the Executive Vice-President, Corporate Development & Strategy at Biota. Prior to joining Biota, Dr. Patti was a co-founder of Inhibitex, Inc., a biopharmaceutical company developing novel therapeutics for a variety of bacterial and viral infections. Inhibitex was acquired by Bristol Myers Squibb in February 2012. Prior to the acquisition, Dr. Patti was Inhibitex's Chief Scientific Officer as well as the Senior Vice President, Research & Development. Prior to founding Inhibitex, Dr. Patti was a Research Assistant Professor at Texas A&M's Institute of Biosciences and Technology and was focused on the molecular aspects of bacterial -- host interactions. From 1996 to 1998, he also served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, a M.S.P.H. from the University of Miami, School of Medicine and a Ph.D. in Biochemistry from the University of Alabama at Birmingham.